MiNK Therapeutics (INKT) AI Stock Analysis

• Market Cap: $34.71M
• Dividend Yield: N/A
• Average Volume (3M): 10.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: N/A
• EPS Growth: 55.52%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -2.91
• Shares Outstanding: 3,966,392
• 10 Day Avg. Volume: 7,219
• 30 Day Avg. Volume: 10,053
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -5.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $21.00
• Price Target Upside: 140.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

MiNK Therapeutics' stock score reflects the financial challenges inherent in its business model, with significant reliance on future product development and external financing. While technical indicators show some positive momentum, and the earnings call highlighted strategic progress, the valuation and financial instability present substantial risks. The company's efforts in clinical advancements and strategic partnerships are positive, but they need to be supported by stronger financial fundamentals to improve the overall outlook.

Positive Factors

Clinical Trial Progress

The majority of patients in the Phase 2 gastric study are now enrolled, with robust initial efficacy data expected to guide future developments.

Funding and Financial Strategy

Acceptance of funding from NIAID for the upcoming GvHD study is considered a positive development for the company.

Negative Factors

Data Transparency

No data were provided on the study's primary or secondary endpoints.

Financial Risk

Reducing price target to $4/share to account for risks associated with potential future dilution.

MiNK Therapeutics Business Overview & Revenue Model

Company Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

How the Company Makes Money

MiNK Therapeutics makes money through the research and development of its iNKT cell therapies, which are primarily funded through a combination of private investments, public offerings, and strategic partnerships. The company generates revenue by entering into collaboration agreements with larger pharmaceutical companies who are interested in its proprietary technology platform. These partnerships may include upfront payments, milestone payments based on developmental progress, and royalties on future sales if the therapies are successfully commercialized. Additionally, MiNK might receive grants or other funding from governmental and non-governmental organizations to support its research initiatives.

MiNK Therapeutics Financial Statement Overview

Summary

MiNK Therapeutics is facing significant financial challenges typical of a biotech in early stages, with no revenue and consistent losses. The balance sheet shows financial instability with negative equity, but no debt provides some flexibility. Cash flows are negative, relying on external financing rather than operations.

Income Statement

MiNK Therapeutics has consistently reported zero revenue in recent years, indicating a lack of commercialized products or services. The company has experienced substantial net losses, with a significant negative net profit margin. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high expenses relative to nonexistent revenues. These financial challenges suggest the company is still in a developmental phase, typical for biotechnology firms, but underscore the need for successful product development and commercialization.

Balance Sheet

The company's balance sheet indicates a challenging financial position, with negative stockholders' equity in several years, implying liabilities exceed assets. The absence of debt is positive, but the equity ratio is highly unstable, reflecting past negative equity scenarios. MiNK Therapeutics holds a substantial amount of cash and short-term investments, which might support operations in the short term. The lack of debt provides some financial flexibility, but overall, the balance sheet shows financial instability.

Cash Flow

MiNK Therapeutics has consistently experienced negative operating and free cash flows, indicating ongoing cash consumption without generating cash through operations. Financing activities have been a primary source of cash, which may not be sustainable in the long term. The company's ability to maintain operations relies heavily on external financing rather than operational success. The absence of positive cash flow from operations highlights the need for significant improvements in commercial and operational execution.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	2.70B	0.00	0.00
	Gross Profit
0.00	-204.62K	-28.24B	-28.36B	-55.06K
	EBIT
0.00	-22.92M	-30.95M	-28.36M	-14.64M
	EBITDA
0.00	-22.25M	-30.83M	-27.70M	-13.74M
	Net Income Common Stockholders
-10.78B	-22.46M	-24.78M	-23.11M	-15.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.58B	3.37M	19.64M	38.89M	2.69M
	Total Assets
5.72M	4.55M	21.47M	40.24M	4.56M
	Total Debt
4.92M	0.00	0.00	0.00	43.82M
	Net Debt
347.57K	-3.37M	-19.64M	-38.89M	41.13M
	Total Liabilities
25.31M	22.61M	21.87M	16.47M	58.43M
	Stockholders Equity
-19.59M	-18.06M	-401.30K	23.78M	-53.87M
Cash Flow		Free Cash Flow
-9.56B	-15.84M	-19.12M	-13.08M	-8.43M
	Operating Cash Flow
-9.56B	-15.76M	-18.87M	-12.83M	-8.34M
	Investing Cash Flow
0.00	-73.56K	-250.05K	-248.98K	-95.21K
	Financing Cash Flow
10.82B	-407.17K	-155.60K	49.26M	11.11M

MiNK Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.75
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Positive. The current price of 8.75 is above the 20-day moving average (MA) of 8.49, below the 50-day MA of 8.95, and above the 200-day MA of 8.10, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 62.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INKT.

MiNK Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
CNTB	48 Neutral	$32.66M	―	-58.89%	―	―	―
SRZN	46 Neutral	$38.52M	―	-767.91%	―	―	0.13%
INKT	44 Neutral	$34.71M	―	78.50%	―	―	55.52%
TPST	42 Neutral	$32.50M	―	-182.35%	―	―	21.75%
KZR	41 Neutral	$32.88M	―	-55.00%	―	-100.00%	18.17%
ALXO	38 Underperform	$28.46M	―	-88.91%	―	―	30.37%

MiNK Therapeutics Corporate Events

MiNK Therapeutics Appoints Dr. Robert Kadlec to Board

MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Board, with a term lasting until 2026. Dr. Kadlec’s role includes serving on the Corporate Governance and Nominating Committee, and he has been granted options to purchase shares of MiNK’s stock, vesting over three years. His compensation package includes both cash and equity, aligning with MiNK’s non-employee director program, and his appointment was formally announced via a press release.